PreventiveMD vs Vita Bella
An all-in floor at $83 against a stated rate at $238.
PreventiveMD
Editorial
$83/mo
Two compounded lines described as all-in, at $83 for semaglutide and $97 for tirzepatide by injection. Both are qualified as 'as low as', so both are floors rather than rates, and the dose that sits at the floor is not stated. The $49 monthly membership PreventiveMD charges belongs to its brand plans and does not attach to these two lines. Coverage is stated across 36 states.
Pick it for: Buyers who want the lowest published all-in figure
Vita Bella
Editorial
$238/mo
Compounded semaglutide at $109 and compounded tirzepatide at $159, both stated as medication only and both compounded with B-6. The product pages state a $129 monthly membership is required alongside clinical approval, and a one-time $99 consult applies. A three-month minimum is stated on both products across 46 states.
Pick it for: Buyers who want a figure that is not hedged as a floor
Our verdict
PreventiveMD describes its compounded figures as all-in but qualifies them as 'as low as'. Vita Bella publishes a higher figure with no floor language. Neither states the dose behind it.
What actually separates them
PreventiveMD and Vita Bella state different things about published price and where you can use it. Everything else they publish, they publish the same way.
Vita Bella costs $155 more than PreventiveMD — 187% more for the same molecule. Whether that buys anything is what the rest of this page is for.
Over twelve months that is about $996 at PreventiveMD against $2,856 at Vita Bella — a difference of $1,860.
| PreventiveMD | Vita Bella | |
|---|---|---|
| Published price | $83/mo | $238/mo |
| Where you can use it | 36 states | 46 states |
Before you choose either
Ask both sellers what dose the monthly price buys before you compare the two figures. A price is only a price once you know what quantity it is attached to, and a seller that will not answer has told you something. Set both against every published price we hold rather than against each other alone.
Our take is computed from a published rubric that does not read commercial status, and what is known about safety applies to both of them equally.